Chronic cyclosporine nephrotoxicity

Current Opinion in Nephrology and Hypertension

Volumn 7, Issue 3, 1998, Pages 265-270

  Andoh, Takeshi F ^a   Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; CALBINDIN; CALCIUM; COLLAGEN TYPE 1; CREATININE; CYCLOPHILIN; CYCLOSPORIN; CYTOKINE; ENDOTHELIN; FIBRONECTIN; INTERLEUKIN 2; MAGNESIUM; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHATASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAPAMYCIN; SCLEROPROTEIN; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; AUTOIMMUNE DISEASE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BLOOD FLOW; KIDNEY CALCIFICATION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 0031864078     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199805000-00005     Document Type: Article

References (29)

1. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive drugs - experimental and clinical observations. Semin Nephrol 1997; 17:34-45.
2. Kaputlu I, Sadan G, Karayalcin B, Boz A. Beneficial effects of pentoxifylline on cyclosporine-induced nephrotoxicity. Clin Exp Pharmacol Physiol 1997; 24:365-369.
3. Hilbrands LB, Hoitsma AG, Wetzels JF, Koene RA. Detailed study of changes in renal function after conversion from cydosporine to azathioprine. Clin Nephrol 1996; 45:230-235.
4. Thurman RG, Zhong Z, Vonfrankenberg M, Stachlewitz RF, Bunzendahl H. Prevention of cyclosporine-induced nephrotoxicity with dietary glycine. Transplantation 1997; 63:1661-1667.
5. Chan C, Maurer J, Cardella C, Cattran D, Pei Y. A randomized controlled triple of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation 1997; 63:1435-1440.
6. Shin GT, Cheigh JS, Riggio RR, Suthanthiran M, Stubenbord WT, Serur D, et al. Effect of nifedipine on renal allograft function and survival beyond one year. Clin Nephrol 1997; 47:33-36.
7. Maestri M, Dafoe DC, Adams GA, Gaspari A, Luzzana F, Innocente F, et al. Insulin-like growth factor-1 ameliorates delayed kidney graft function and the acute nephrotoxic effects of cyclosporine. Transplantation 1997; 64:185-190.
8. Carmellini M, Frosini F, Filipponi F, Boggi U, Mosca F. Effect of cilastatin on cyclosporine-induced acute nephrotoxicity in kidney transplant recipients. Transplantation 1997; 64:164-166.
9. Assis SM, Monteiro JL, Seguro AC. L-arginine and allopurinol protect against cyclosporine nephrotoxicity. Transplantation 1997; 63:1070-1073.
10. Kasiske BL, Johnson HJ, Goerdt PJ, Heimduthoy KL, Rao VK, Dahl DC, et al. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients. Am J Kidney Dis 1997; 30:639-645.
11. Lipkin GW, Thuraisingham R, Dawnay ABS, Harwood SM, Raine AEG. Acute reversal of cyclosporine nephrotoxicity by neutral endopeptidase inhibition in stable renal transplant recipients. Transplantation 1997; 64:1007-1017.
12. Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model, Transplantation 1996; 62:311-316.
13. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997; 63:664-668. Although cyclosporine remains the central immunosuppressive agent for cardiac allograft recipients, its use leads to a greater than one-third decrease in creatinine clearance by 6 months after transplantation and progression to end-stage renal failure, requiring hemodialysis in 6.5% of cardiac transplant recipients. Moreover, these patients are at increased risk of death compared with other cardiac allograft recipients. This paper warrants the search for alternative or adjunctive agents that would allow decreased dosing or reduced nephrotoxicity of cyclosporine, while maintaining equivalent survival.
14. Kon SP, Templar J, Dodd SM, Rudge CJ, Raftery MJ. Diagnostic contribution of renal allograft biopsies at various intervals after transplantation. Transplantation 1997; 63:547-550.
15. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C. et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996; 35:710-719. This paper evaluated the efficacy and toxicity of systemic cyclosporine in patients with severe psoriasis, observing short-term (12 weeks) and long-term (3-5 years) effects. Older patients experience cyclosporine-induced hypertension and nephrotoxicity more frequently than do younger patients.
16. 1 and matrix proteins in cyclosporine-induced renal fibrosis.
17. Andoh TF, Lam TT, Lindsley J, Alpers CE, Bennett WM. Enhancement of chronic cyclosporine nephrotoxicity by sodium depletion in an experimental mouse model. Nephrology 1997; 3:471-478.
18. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology 1996; 103:365-373.
19. Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 1995; 48 (Suppl 52):S63-S69.
20. Lewis RM. Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Kidney Int 1995; 48 (Suppl 52):S75-S78.
21. Hansen JM, Foghandersen N, Christensen NJ, Strandgaard S. Cyclosporine-induced hypertension and decline in renal function in healthy volunteers. J Hypertens 1997; 15:319-326.
22. Lafayette RA, Mayer G, Meyer TW. The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. J Am Soc Nephrol 1993; 3:1892-1899.
23. Andoh TF, Gardner MP, Bennetl WM. Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity. Transplantation 1997; 64:1236-1240. This paper indicates that chronic cyclosporine nephrotoxicity can be aggravated by NO blockade and ameliorated by NO enhancement, suggesting that NO has an important role in the mechanism of chronic cyclosporine nephropathy.
24. 1 a potent immunosuppressive cytokine.
25. 1 expression.
26. Pichler RH, Hugo C, Shankland SJ, Reed MJ, Bassuk JA, Andoh TF, et al. Sparc is expressed in renal interstitial fibrosis and in renal vascular injury. Kidney Int 1996; 50:1978-1989.
27. 1 receptor, and may be implicated in the pathogenesis of renal interstitial fibrosis.
28. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and fk506. Kidney Int 1996; 50:1110-1117.
29. r protein levels, no noticeable alterations in calcium metabolism, and no renal calcification. This paper provides evidence for a link between decreased renal calbindin, increased calcium urine excretion, and intratubular kidney calcification.